Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the initiation of the global Phase 3 platinum resistant ovarian cancer (PROC) clinical trial in China for the development of Aravive’s batiraxcept.
Lucid Diagnostics Strengthens And Expands Market Access And Direct Contracting Efforts; Shaun M. O’Neil Promoted To Lucid’s President And COO
Industry veterans join executive team as VP, Market Access and VP, Employer MarketsShaun M. O'Neil promoted to Lucid's President and COONEW YORK, Nov. 16, 2023 /PRNewswire/ -- Lucid Diagnostics
